{"url_path":"/sec/hnge/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1673743/0001628280-26-040802-index.html","accession_number":"0001628280-26-040802","cik":"0001673743","ticker":"HNGE","issuer_name":"Hinge Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1673743/0001628280-26-040802-index.html","primary_entity_key":"0001673743","primary_entity_name":"Hinge Health, Inc."},"word_count":500,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 3, 2026, Hinge Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company’s stockholders voted on two proposals at the Annual Meeting, each of which is described below as well as more fully in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 17, 2026 (the “Proxy Statement”). Holders of the Company’s Class A common stock were entitled to one (1) vote for each share held as of the close of business on April 10, 2026 (the “Record Date”), holders of the Company’s Class B common stock were entitled to fifteen (15) votes for each share held as of the close of business on the Record Date and holders of the Company’s Series E preferred stock were entitled to the number of votes based on the number of shares of common stock into which such share of Series E preferred stock could be converted to as of the Record Date. The shares of Series E preferred stock were not entitled to vote in connection with Proposal No. 1: the Election of Class I Directors. The Class A common stock, Class B common stock and Series E preferred stock voted as a single class on all matters at the Annual Meeting for which such class or series was entitled to vote.\n\nAt the Annual Meeting, the Company’s stockholders voted on the following proposals:\n\n1.To elect each of Teddie Wardi and Tyler Sloat as Class I directors to serve until the Company’s 2029 annual meeting of stockholders and until such director’s successor is duly elected and qualified, or until such director’s earlier death, resignation, disqualification, retirement or removal; and\n\n2.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\nThe final voting results for each of these proposals are as follows:\n\nProposal 1: Election of Class I Director Nominees.\n\nNomineesVotes ForVotes WithheldBroker Non-Votes\n\n Teddie Wardi276,921,91114,888,63114,168,983\n\n Tyler Sloat291,330,022480,52014,168,983\n\nBased on the votes set forth above, each of the nominees, Teddie Wardi and Tyler Sloat, were elected to serve as Class I directors until the Company’s 2029 annual meeting of stockholders and until such director’s successor is duly elected and qualified, or until such director’s earlier death, resignation, disqualification, retirement or removal.\n\nProposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.\n\nVotes ForVotes AgainstAbstentions\n\n305,789,374121,05869,093\n\nBased on the votes set forth above, the stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. There were no broker non-votes on this proposal.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nHINGE HEALTH, INC.\n\nDate: June 4, 2026\nBy:\n\n/s/ James Budge\n\nJames Budge, Chief Financial Officer"}